Europe Hormone Replacement Therapy Market

Europe Hormone Replacement Therapy Market Size (2024 to 2029)

The size of the Europe hormone replacement therapy market is expected to be valued at USD 4.99 billion in 2024 and USD 6.91 billion by 2029, growing at a CAGR of 6.75% during the forecast period.

The European Hormone replacement therapy market is projected to be fueled by the increased awareness of postmenopausal concerns among women, research and development activities, and growing healthcare spending.

Other notable growth factors are the availability of new formulations and unmet medical needs that necessitate hormone treatment. Treatment with estrogen or a combination of estrogen and progestogen is commonly defined as hormone replacement therapy in post-menopause women.Menopause-related hormonal changes are the most commonly reported side effect of growing older. The average age of onset of menopause in women is around 50 years. By the age of 50, the level of estrogen and progesterone produced by women has significantly decreased. The pituitary gland compensates for estrogen and progesterone production decline by increasing follicle-stimulating hormone output (FSH). Women’s post-menopause symptoms, such as flushing, are a physical manifestation of this. As a result of these age-related problems, the demand for hormone replacement therapy increases, propelling the market under investigation. Furthermore, rising product approvals and increasing research and development activities by key players in creating innovative therapeutics for the treatment of hormonal imbalances are likely to contribute to the positive growth of the studied market throughout the forecast period.The risk of side effects like bleeding, bloating, mood swings, and nausea, as well as breast soreness or enlargement, headaches, and the risk of breast cancer, heart disease, and stroke, is stifling the market’s expansion. In addition, the high expense of therapy is a significant barrier. This limits its appeal to middle-class consumers, particularly in Central and Eastern Europe’s rising markets. Furthermore, women with a high risk of coronary artery disease, which affects many women in Europe, are discouraged from using hormone replacement treatment.

This research report on the Europe Hormone Replacement Therapy Market has been segmented and sub-segmented into the following categories

Europe Hormone Replacement Therapy Market Analysis By Hormone Type

• Estrogen Replacement Therapy
• Growth Hormone Replacement Therapy
• Thyroid replacement therapy
• others

Europe Hormone Replacement Therapy Market Analysis By Route of Administration

• Oral
• Transdermal
• Parenteral
• other routes

Europe Hormone Replacement Therapy Market Analysis By Country

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

Geographically, Europe is predicted to register significant growth in the Hormone replacement therapy market. The increased drug development drives market growth with novel delivery systems and hormonal imbalance disorders with the growing senior population. The expansion of the European hormone replacement therapy market is contributed by countries such as France, Germany, the United Kingdom, Spain, Italy, and the rest of Europe.

Furthermore, the rising prevalence of postmenopausal symptoms in women and dwarfism are driving the need for hormone replacement therapy.

In addition, the increasing use of hormonal replacement therapy among transgender persons in Russia and the establishment of hormone medication manufacturing facilities are expected to boost the market growth.The UK hormone replacement therapy market accounted for the most significant share of the global market. Increased demand for hormone replacement and a shift to non-hormonal therapy is credited with driving the market. Also, the launch of new drug initiatives by significant stakeholders is one of the primary growth factors in the United Kingdom. The National Institute for Health and Care Excellence (NICE) strongly recommends growth hormone replacement therapy for children with inadequate growth.According to research published in Italy in 2023, HRT use in women is uncommon. In addition, the national pharmaceutical agency offers free hormone replacement therapy, boosting the market growth. France offers a plethora of potential for the hormone replacement therapy sector, with more than 50 percent of women experiencing menopause symptoms taking hormone replacement therapy.

KEY MARKET PLAYERS

Key players operating in the Europe Hormone Replacement Therapy Market profiled in this report are Novartis, Abbott Laboratories, Pfizer, Mylan Laboratories, F. Hoffmann-La Roche, Merck & Co, Amgen, Eli Lily, Bayer, Novo Nordisk, Wyeth, Hisamitsu Pharmaceutical Co. Inc.,